Investigational drug · Phase 2
Zalifrelimab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "Zalifrelimab"
First trial start
2021
Sep 1, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zalifrelimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Prostate Cancer
- Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma
Approved drugs for the same conditions: Prostate cancer · Pancreatic cancer · Head and neck cancer · Oncology · Kidney and urology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Zalifrelimab" as an intervention, largest first.
Agenus Inc.Industry
NCT03495882 · 175 participants · Start Dec 18, 2017 · Primary completion Jul 15, 2022
Drug: Zalifrelimab; Balstilimab · For: Cervical Cancer
Sites: Goodyear, Arizona; Duarte, California; Miami, Florida · 47 sites in all
Agenus Inc.Industry
NCT02694822 · 89 participants · Start Apr 2016 · Primary completion Mar 30, 2022
Drug: Zalifrelimab · For: Advanced Solid Cancers; Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Sites: Duarte, California; Los Angeles, California; Denver, Colorado · 11 sites in all
- A Study of Evofosfamide in Combination With Zalifrelimab and BalstilimabActive, not recruiting
ImmunoGenesisIndustry
NCT06782555 · 71 participants (planned) · Start Jan 8, 2025 · Primary completion Oct 2027
Drug: Evofosfamide; Zalifrelimab and 1 more · For: Metastatic Prostate Cancer; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Pancreatic Cancer
Sites: Houston, Texas
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasActive, not recruiting
University of Colorado, DenverAcademic, hospital or other
NCT04028063 · 65 participants (planned) · Start Jan 28, 2020 · Primary completion Apr 7, 2027
Drug: Balstilimab; Zalifrelimab and 2 more · For: Metastatic Soft Tissue Sarcoma; Advanced Soft Tissue Sarcoma
Sites: Aurora, Colorado
UroGen Pharma Ltd.Industry
NCT05375903 · 51 participants · Start Jun 1, 2022 · Primary completion Jan 9, 2026
Drug: UGN-301; UGN-201 and 1 more · For: Non-muscle Invasive Bladder Cancer; NMIBC; Carcinoma in Situ of Bladder and 3 more
Sites: Little Rock, Arkansas; Los Angeles, California; Tampa, Florida · 13 sites in all
Ann & Robert H Lurie Children's Hospital of ChicagoAcademic, hospital or other
NCT04943848 · 36 participants (planned) · Start Jan 10, 2022 · Primary completion Sep 2026
Drug: rHSC-DIPGVax; Balstilimab and 1 more · For: Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant
Sites: Orange, California; Chicago, Illinois; Boston, Massachusetts
- Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic CancerActive, not recruiting
Nelum CorpIndustry
NCT04827953 · 28 participants · Start Sep 1, 2021 · Primary completion Apr 2025
Drug: Gemcitabine; Nab paclitaxel and 2 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Santiago de Compostela, Spain; Málaga, Spain; Zaragoza, Spain · 6 sites in all
Agenus Inc.Industry
NCT05033132 · 0 participants · Start Oct 1, 2021 · Primary completion Dec 30, 2024
Drug: Balstilimab; Balstilimab + Zalifrelimab · For: Cervical Cancer
Sites: Bengbu, China; Hefei, China; Wuhu, China · 43 sites in all
- Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)Available
Agenus Inc.Industry
NCT05572970
Drug: Balstilimab; Zalifrelimab · For: Cancer
Sites: Birmingham, Alabama; Tucson, Arizona; Newport Beach, California · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Correction: A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.
Wilky BA, Julian KA, Maleddu A, et al. · Clin Cancer Res 2026
- A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.
Wilky BA, Julian KA, Maleddu A, et al. · Clin Cancer Res 2025
- Beyond Platinum, ICIs in Metastatic Cervical Cancer: A Systematic Review.
Maiorano BA, Maiorano MFP, Ciardiello D, et al. · Cancers (Basel) 2022
- Abscobal Effect of Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer.
Aslan V, Sütcüoğlu O, Özet A, et al. · J Clin Oncol 2022
- Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study.
O'Malley DM, Neffa M, Monk BJ, et al. · J Clin Oncol 2022
- Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
Bose CK · Med Oncol 2022
Also in development for Metastatic Prostate Cancer
- PalacaparibAZD9574Phase 25 trials
AstraZeneca · Metastatic Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- FPI-2265AZD2265, 225Ac-PSMA-I&TPhase 24 trials
Fusion Pharmaceuticals Inc. · Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- AZD2287Imaging agentPhase 22 trials
AstraZeneca · Metastatic Prostate Cancer
- AZD0516Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD0754Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- AZD8359Phase 21 trial
AstraZeneca · Metastatic Prostate Cancer
- GDC-1261Phase 21 trial
Roche (Genentech) · Advanced Prostate Cancer, Metastatic Prostate Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.